Report by the ACNP Task Force on response and remission in major depressive disorder

Neuropsychopharmacology

Volumn 31, Issue 9, 2006, Pages 1841-1853

  Rush, A John ^a   Kraemer, Helena C ^b   Sackeim, Harold A ^c   Fava, Maurizio ^d   Trivedi, Madhukar H ^a   Frank, Ellen ^e   Ninan, Philip T ^f   Thase, Michael E ^e   Gelenberg, Alan J ^g   Kupfer, David J ^e   Regier, Darrel A ^h   Rosenbaum, Jerrold F ^d   Ray, Oakley ⁱ   Schatzberg, Alan F ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia University ^*  (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^h AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

ⁱ VANDERBILT UNIVERSITY   (United States)

Author keywords

Depression; Recovery; Recurrence; Relapse; Remission; Response

Indexed keywords

ARTICLE; CONCEPT FORMATION; EXPERIENCE; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENCE RISK; RELAPSE; REMISSION; SOCIAL INTERACTION; SYMPTOMATOLOGY;

CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; HUMANS; RECURRENCE; RESEARCH DESIGN;

EID: 33747339984     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301131     Document Type: Article

References (117)

1. Agras WS, Crow SJ, Halmi KA, Mitchell JE, Wilson GT, Kraemer HC (2000). Outcome predictors for the cognitive behavior treatment of bulimia nervosa: data from a multisite study. Am J Psychiatry 157: 1302-1308.
2. Alpert JE, Franznick DA, Hollander SB, Fava M (2004). Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. J Clin Psychiatry 65: 1069-1075.
3. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M (2002). Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 14: 33-38.
4. American Academy of Child and Adolescent Psychiatry (1998). Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 37(Suppl 10): 63S-83S.
5. American Psychiatric Association (2000a). Diagnostic and Statistical Manual for Mental Disorders, 4th edn, Text Revision (DSM-IV-TR). American Psychiatric Press: Washington, DC.
6. American Psychiatric Association (2000b). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157(Suppl 4): 1-45.
7. Anderson IM, Nutt DJ, Deakin JFW (2000). Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 14: 3-20.
8. Baca-Garcia E, Blanco C, Saiz-Ruiz J, Rico F, az-Sastre C, Cicchetti DV (2001). Assessment of reliability in the clinical evaluation of depressive symptoms among multiple investigators in a multicenter clinical trial. Psychiatry Res 102: 163-173.
9. Ballenger JC (1999). Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 60(Suppl 22): 29-34.
10. Bauer M, Whybrow PC, Angst J, Versiani M, Miller H-J, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2002a). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3: 5-43.
11. Bauer M, Whybrow PC, Angst J, Versiani M, Moller H-J, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2002b). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3: 69-86.
12. Beasley Jr CM, Nilsson ME, Koke SC, Gonzales JS (2000). Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. J Clin Psychiatry 61: 722-728.
13. Beck AT, Rush AJ, Shaw BF, Emery G (1979). Cognitive Therapy of Depression. Guilford Press: New York.
14. Beck AT, Steer RA, Brown GK (1996). Beck Depression Inventory, 2nd edn. Manual, The Psychological Corporation: San Antonio, TX.
15. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK (1961). An inventory for measuring depression. Arch Gen Psychiatry 4: 561-571.
16. Bielski RJ, Ventura D, Chang CC (2004). A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65: 1190-1196.
17. Canadian Psychiatric Association Network for Mood and Anxiety Treatments (2001). Clinical Guidelines for the Treatment of Depressive Disorders. Can J Psychiatry 46(Suppl 1): 5S-90S.
18. Carmody T, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D et al (in press). The Montgomery Äsberg and the Hamilton Ratings of depression: a comparison of measures. Eur Neuropsychopharmacol.
19. Chilvers C, Dewey M, Fielding K, Gretton V, Miller P, Palmer B et al (2001). Counseling versus antidepressants in Primary Care Study Group. Antidepressant drugs and generic counseling for treatment of major depression in primary care: randomised trial with patient preference arms. BMJ 322: 772-775.
20. Cohen J (1983). The cost of dichotomization. Appl Psychol Meas 7: 249-253.
21. Cook RJ, Sackett DL (1995). The number needed to treat: a clinically useful measure of treatment effect. Br Med J 310: 452-454.
22. Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA et al, Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder (1999). The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 60: 142-156.
23. Daly JJ, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S et al (2001). ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord 3: 95-104.
24. Dawson MY, Michalak EE, Waraich P, Anderson JE, Lam RW (2004). Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis. BMC Fam Pract 5: 19.
25. Depression Guideline Panel (1993). Clinical Practice Guideline, Number 5: Depression in Primary Care: Volume 2. Treatment of Major Depression. US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR Publication No. 93-0551: Rockville, MD.
26. Dobrovolny CL, Ivey FM, Rogers MA, Sorkin JD, Macko RF (2003). Reliability of treadmill exercise testing in older patients with chronic hemiparetic stroke. Arch Phys Med Rehabil 84: 1308-1312.
27. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of life enjoyment and statisfaction questionnaire: a new measure. Psychopharmacol Bull 29: 321-326.
28. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The global assessment scale: a procedure for measuring the overall severity of psychiatric disturbance. Arch Gen Psychiatry 33: 766-771.
29. Entsuah AR, Huang H, Thase ME (2001). Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 62: 869-877.
30. Ezquiaga E, Garcia A, Pallares T, Bravo MF (1999). Psychosocial predictors of outcome in major depression: a prospective 12-month study. J Affect Disord 52: 209-216.
31. Fava GA, Fabbri S, Sonino N (2002). Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry 26: 1019-1027.
32. Fava M, Evins AE, Dorer DJ, Schoenfeld DA (2003a). The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72: 115-127.
33. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM (2004). The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 65: 521-530.
34. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA et al (2003b). Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26: 457-494, x.
35. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF (1997). Major depressive subtypes and treatment response. Biol Psychiatry 42: 568-576.
36. Fears TR, Ziegler RG, Donaldson JL, Falk RT, Hoover RN, Stanczyk FZ et al (2002). Reproducibility studies and interlaboratory concordance for androgen assays of male plasma hormone levels. Cancer Epidemiol Biomarkers Prev 11: 785-789.
37. Frank E, Kupfer DJ, Gerebtzoff A, Meya U, Laghrissi-Thode F, Grochocinski VJ et al (2001). The development of study exit criteria for evaluating antimanic compounds. J Clin Psychiatry 62: 421-425.
38. Frank E, Prien RF, Jarrett JB, Keller MB, Kupfer DJ, Lavori P et al (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder: response, remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48: 851-855.
39. Fritzler MJ, Wiik A, Tan EM, Smolen JS, McDougal JS, Chan EK et al (2003). A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J Rheumatol 30: 2374-2381.
40. Ghatavi K, Nicolson R, MacDonald C, Osher S, Levitt A (2002). Defining guilt in depression: a comparison of subjects with major depression, chronic medical illness and healthy controls. J Affect Disord 68: 307-315.
41. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA (2004). Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24: 389-399.
42. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
43. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278-296.
44. Hirschfeld RM, Dunner DL, Keitner G, Klein DN, Koran LM, Kornstein SG et al (2002). Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 51: 123-133.
45. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F et al (1997). The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277: 333-340.
46. Hollon SD, Kendall PC (1980). Cognitive self-statements in depression: development of an automatic thoughts questionnaire. Cognitive Ther Res 4: 383-397.
47. Husain MM, Rush AJ, Fink M, Knapp R, Petrides G, Rummans T et al (2004). Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a consortium for research in ECT (CORE) report. J Clin Psychiatry 65: 485-491.
48. Iosifescu DV, Nierenberg AA, Alpert JE, Smith M, Bitran S, Dording C et al (2003). The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 160: 2122-2127.
49. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W et al (1998a). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55: 694-700.
50. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W et al (1998b). Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50: 97-108.
51. Judd LL, Paulus MP, Zeller P (1999). The role of residual subthreshold depressive symptoms in early episode relapse in unipolar major depressive disorder. Arch Gen Psychiatry 56: 764-765.
52. Kanai T, Takeuchi H, Furukawa TA, Yoshimura R, Imaizumi T, Kitamura T et al (2003). Time to recurrence after recovery from major depressive episodes and its predictors. Psychol Med 33: 839-845.
53. Keitner GI, Ryan CE, Miller IW, Kohn R, Epstein NB (1991). 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry 148: 345-350.
54. Keitner GI, Ryan CE, Miller IW, Norman WH (1992). Recovery and major depression. factors associated with twelve-month outcome. Am J Psychiatry 149: 93-99.
55. Keller MB, Gelenberg AJ, Hirschfeld RM, Rush AJ, Thase ME, Kocsis JH et al (1998). The treatment of chronic depression part 2. a double-blind randomized trial of sertraline and imipramine. J Clin Psychiatry 59: 598-607.
56. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ et al (2000). A comparison of nefazodone the cognitive behavioral-analysis system of psychotherapy and their combination for the treatment of chronic depression. N Engl J Med 342: 1462-1470.
57. Kendler KS (1996). Major depression and generalized anxiety disorder. Same genes (partly) different environments - revisited. Br J Psychiatry Suppl 30: 68-75.
58. Klerman GL, Weissman MM, Rounsaville BJ, Chevron RS (1984). Interpersonal Psychotherapy of Depression. Basic Books: New York.
59. Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C et al (2001). Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 65: 27-36.
60. Kraemer HC, Wilson GT, Fairburn CG, Agras WS (2002). Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 59: 877-883.
61. Kroenke K, Spitzer RL, Williams JB (2001). The PHQ-9. Validity of a brief depression severity measure. J Gen Intern Med 16: 606-613.
62. Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I et al (1998). A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59: 528-534.
63. Miller IW, Keitner GI, Schatzberg AJ, Klein DN, Thase ME, Rush AJ et al (1998). The treatment of chronic depression. Part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 59: 608-619.
64. Mintz J, Mintz LI, Arruda MJ, Hwang SS (1992). Treatments of depression and the functional capacity to work (published erratum appears in Arch Gen Psychiatry 1993 Mar; 50(3): 241). Arch Gen Psychiatry 49: 761-768.
65. Montgomery SA, Äsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
66. Montgomery SA, Huusom AK, Bothmer J (2004). A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50: 57-64.
67. Nelson JC, Mazure CM, Jatlow PI, Bowers Jr MB, Price LH (2004). Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 55: 296-300.
68. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J (1994). Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 14: 419-423.
69. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington III JJ et al (1999). Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60: 221-225.
70. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M (1995). Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 152: 1500-1503.
71. O'Leary D, Costello F, Gormley N, Webb M (2000). Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients. J Affect Disord 57: 159-171.
72. Ormel J, Oldehinkel AJ, Nolen WA, Vollebergh W (2004). Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Arch Gen Psychiatry 61: 387-392.
73. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A (1995). Residual symptoms after partial remission. an important outcome in depression. Psychol Med 25: 1171-1180.
74. Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R et al (1999). Prevention of relapse in residual depression by cognitive therapy. A controlled trial. Arch Gen Psychiatry 56: 829-835.
75. Perlis RH, Iosifescu DV, Alpert J, Nierenberg AA, Rosenbaum JF, Fava M (2004). Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics 45: 224-229.
76. Philipp M, Fickinger MP (1993). The definition of remission and its impact on the length of a depressive episode. Arch Gen Psychiatry 50: 407-408.
77. President's New Freedom Commission on Mental Health (2003). Achieving the Promise: Transforming Mental Health Care in America, Final Report (Pub. No. SMA-03-3832). DHHS: Rockville, MD.
78. Prien RF, Kupfer DJ (1986). Continuation drug therapy for major depressive episodes. How long should it be maintained? Am J Psychiatry 143: 18-23.
79. Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S et al (1996). Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 153: 985-992.
80. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA (2004). Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 55: 301-312.
81. Prudic J, Sackeim HA, Devanand DP (1990). Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 31: 287-296.
82. Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J et al (2003). When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 160: 734-740.
83. Reesal RT, Lam RW, CANMAT Depression Work Group (2001). Clinical guidelines for the treatment of depressive disorders. II. Principles of management. Can J Psychiatry 46(Suppl 1): 21S-28S.
84. Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J et al (1998). Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 155: 1247-1253.
85. Riso LP, Thase ME, Howland RH, Friedman ES, Simons AD, Tu XM (1997). A prospective test of criteria for response remission relapse recovery and recurrence in patients treated with cognitive behavior therapy. J Affect Disord 43: 131-142.
86. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC et al (2006). An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 59: 493-501 (Epub 2005 Sep 30).
87. Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Trivedi MH et al (2003a). Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry 64: 357-369.
88. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA et al (2004). Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25: 119-142.
89. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996). The Inventory of Depressive Symptomatology (IDS). Psychometric properties. Psychol Med 26: 477-486.
90. Rush AJ, Ryan ND (2002). Current and emerging therapeutics for depression. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds). Neuropsychopharmacology. The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 1081-1095.
91. Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM et al (2005a). Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 58: 355-363.
92. Rush AJ, Thase ME, Dube S (2003b). Research issues in the study of difficult-to-treat depression. Biol Psychiatr 53: 743-753.
93. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN et al (2003c). The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR). A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54: 573-583.
94. Rush AJ, Zimmerman M, Wisniewski SR, Fava M, Hollon SD, Warden D et al (2005b). Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. J Affect Disord 87: 43-55.
95. Sackeim HA, Decina P, Prohovnik I, Malitz S (1987). Seizure threshold in electroconvulsive therapy. Effects of sex, age, electrode placement, and number of treatments. Arch Gen Psychiatry 44: 355-360.
96. Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM et al (2001). Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 285: 1299-1307.
97. Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S (1990). The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 10: 96-104.
98. Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ et al (1993). Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy (see comments). N Engl J Med 328: 839-846.
99. Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S et al (2000). A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 57: 425-434.
100. Sayer NA, Sackeim HA, Moeller JR, Prudic J, Devanand DP, Coleman EA et al (1993). The relations between observer-rating and self-report of depressive symptomatology. Psychol Assess 5: 350-360.
101. Simon GE, Manning WG, Katzelnick DJ, Pearson SD, Henk HJ, Helstad CS (2001). Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch Gen Psychiatry 58: 181-187.
102. Small GW, Birkett M, Meyers BS, Koran LM, Bystritsky A, Nemeroff CB (1996). Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group. J Am Geriatr Soc 44: 1220-1225.
103. Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J (1998). Outcome definitions and predictors in depression. Psychother Psychosom 67: 266-270.
104. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178: 234-241.
105. Thase ME, Simons AD, McGeary J, Cahalane JF, Hughes C, Harden T et al (1992). Relapse after cognitive behavior therapy of depression. potential implications for longer courses of treatment. Am J Psychiatry 149: 1046-1052.
106. Trivedi MH, DeBattista C, Fawcett J, Nelson C, Osser DN, Stein D et al (1998). Developing treatment algorithms for unipolar depression in cyberspace. International Psychopharmacology Algorithm Project (IPAP). Psychopharmacol Bull 34: 355-359.
107. Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ et al (2004a). Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 61: 669-680.
108. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T et al (2004b). The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 34: 73-82.
109. Trivedi MH, Rush AJ, Pan JY, Carmody TJ (2001). Which depressed patients respond to nefazodone and when? J Clin Psychiatry 62: 158-163.
110. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al, for the STAR*D Study Team (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
111. Viinamaki H, Hintikka J, Tanskanen A, Honkalampi K, Antikainen R, Koivumaa-Honkanen H et al (2002). Partial remission in major depression. a two-phase, 12-month prospective study. Nord J Psychiatry 56: 33-37.
112. Ware Jr JE, Sherbourne CD (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473-483.
113. Weissman AN (1979). The dysfunctional attitude scale. A validation study. Diss Abst Int 40: 1389B-1390B.
114. Wilson JF, Watson ID, Williams J, Toseland PA, Thomson AH, Sweeney G et al (2002). Primary standardization of assays for anticonvulsant drugs: comparison of accuracy and precision. Clin Chem 48: 1963-1969.
115. Zimmerman M, Chelminski I, Posternak M (2004a). A review of studies of the Montgomery-Äsberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. Int Clin Psychopharmacol 19: 1-7.
116. Zimmerman M, Posternak MA, Chelminski I (2004b). Defining remission on the Montgomery-Äsberg depression rating scale. J Clin Psychiatry 65: 163-168.
117. Zimmerman M, Posternak MA, Chelminski I (2004c). Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol 19: 215-220.